Abstract

This paper analysed the clinical efficacy of cisplatin intrapleural perfusion with pemetrexed disodium in the treatment of lung adenocarcinoma complicated with malignant pleural effusion and its influence on carcinoembryonic antigen levels in pleural effusion. 105 patients having lung adenocarcinoma with malignant pleural effusion who were admitted between July 2018 and July 2022 were selected and divided into research (n=55) and control group (n=50). Patients of the research group received cisplatin intrapleural perfusion with pemetrexed disodium and the control group patients were treated with carboplatin intrapleural perfusion along with pemetrexed disodium was given. Data of clinical efficacy, adverse reactions like fatigue, fever, gastrointestinal discomfort, decreased white blood cell count and reduced neutrophil count were analysed. Similarly pleural effusion volume, pleural effusion tumor markers like carcinoembryonic antigen, neuron specific enolase and pulmonary function were comparatively analysed. Further, maximal voluntary ventilation and forced expiratory volume in 1 s/forced vital capacity were collected for comparative analysis. Results showed higher total effective rate of treatment with markedly lower incidence of adverse reactions and smaller pleural effusion volume in research group compared with control group. Besides, evidently reduced levels of pleural effusion tumor markers and elevated pleural effusion indices in research group vs. control group were determined after treatment. It is suggested that cisplatin intrapleural infusion with pemetrexed disodium is effective in the treatment of lung adenocarcinoma with malignant pleural effusion, which can significantly inhibit carcinoembryonic antigen levels, reduce pleural effusion volume and improve pulmonary function while ensuring treatment safety.